232 related articles for article (PubMed ID: 36900029)
1. Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions.
Czekierdowski A; Stachowicz N; Smolen A; Łoziński T; Guzik P; Kluz T
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900029
[TBL] [Abstract][Full Text] [Related]
2. Sonographic Assessment of Complex Ultrasound Morphology Adnexal Tumors in Pregnant Women with the Use of IOTA Simple Rules Risk and ADNEX Scoring Systems.
Czekierdowski A; Stachowicz N; Smoleń A; Kluz T; Łoziński T; Miturski A; Kraczkowski J
Diagnostics (Basel); 2021 Feb; 11(3):. PubMed ID: 33671023
[TBL] [Abstract][Full Text] [Related]
3. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.
Hiett AK; Sonek JD; Guy M; Reid TJ
Ultrasound Obstet Gynecol; 2022 May; 59(5):668-676. PubMed ID: 34533862
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of IOTA Simple Rules, IOTA ADNEX Model, RMI, and Subjective Assessment for Preoperative Adnexal Mass Evaluation: The Experience of a Tertiary Care Referral Hospital.
Vilendecic Z; Radojevic M; Stefanovic K; Dotlic J; Likic Ladjevic I; Dugalic S; Stefanovic A
Gynecol Obstet Invest; 2023; 88(2):116-122. PubMed ID: 36716716
[TBL] [Abstract][Full Text] [Related]
5. Application of Ultrasound Scores (Subjective Assessment, Simple Rules Risk Assessment, ADNEX Model, O-RADS) to Adnexal Masses of Difficult Classification.
Pelayo M; Sancho-Sauco J; Sánchez-Zurdo J; Perez-Mies B; Abarca-Martínez L; Cancelo-Hidalgo MJ; Sainz-Bueno JA; Alcázar JL; Pelayo-Delgado I
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685323
[TBL] [Abstract][Full Text] [Related]
6. Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer.
Pozzati F; Sassu CM; Marini G; Mascilini F; Biscione A; Giannarelli D; Garganese G; Fragomeni SM; Scambia G; Testa AC; Moro F
Ultrasound Obstet Gynecol; 2023 Oct; 62(4):594-602. PubMed ID: 37204769
[TBL] [Abstract][Full Text] [Related]
7. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk.
Hidalgo JJ; Ros F; Aubá M; Errasti T; Olartecoechea B; Ruiz-Zambrana Á; Alcázar JL
Ultrasound Obstet Gynecol; 2019 May; 53(5):693-700. PubMed ID: 30353585
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
Yang Y; Ju H; Huang Y
Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
[TBL] [Abstract][Full Text] [Related]
9. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.
Davenport C; Rai N; Sharma P; Deeks JJ; Berhane S; Mallett S; Saha P; Champaneria R; Bayliss SE; Snell KI; Sundar S
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011964. PubMed ID: 35879201
[TBL] [Abstract][Full Text] [Related]
10. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
11. Two-Step Strategy for Optimizing the Preoperative Classification of Adnexal Masses in a University Hospital, Using International Ovarian Tumor Analysis Models: Simple Rules and Assessment of Different NEoplasias in the adneXa Model.
Esquivel Villabona AL; Rodríguez JN; Ayala N; Buriticá C; Gómez AC; Velandia AM; Rodríguez N; Alcázar JL
J Ultrasound Med; 2022 Feb; 41(2):471-482. PubMed ID: 33890698
[TBL] [Abstract][Full Text] [Related]
12. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods.
Meys EMJ; Jeelof LS; Achten NMJ; Slangen BFM; Lambrechts S; Kruitwagen RFPM; Van Gorp T
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):784-792. PubMed ID: 27514486
[TBL] [Abstract][Full Text] [Related]
13. The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors.
Janas L; Stachowiak G; Glowacka E; Piwowarczyk I; Kajdos M; Soja M; Masternak M; Nowak M
Ginekol Pol; 2023 Jan; ():. PubMed ID: 36597746
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
[TBL] [Abstract][Full Text] [Related]
16. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
17. Evaluating use of IOTA two-step strategy to classify adnexal masses identified in pregnancy: pilot study.
Barcroft J; Pandrich M; Del Forno S; Cooper N; Linton-Reid K; Landolfo C; Timmerman D; Saso S; Bourne T
Ultrasound Obstet Gynecol; 2024 May; ():. PubMed ID: 38787921
[TBL] [Abstract][Full Text] [Related]
18. Performance of the IOTA ADNEX model combined with HE4 for identifying early-stage ovarian cancer.
Yang S; Tang J; Rong Y; Wang M; Long J; Chen C; Wang C
Front Oncol; 2022; 12():949766. PubMed ID: 36185223
[TBL] [Abstract][Full Text] [Related]
19. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China.
He P; Wang JJ; Duan W; Song C; Yang Y; Wu QQ
J Ovarian Res; 2021 Dec; 14(1):169. PubMed ID: 34857005
[TBL] [Abstract][Full Text] [Related]
20. Reliability of IOTA score and ADNEX model in the screening of ovarian malignancy in postmenopausal women.
Nohuz E; De Simone L; Chêne G
J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):103-107. PubMed ID: 29709594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
